New Delhi, December 07 (India Science Wire): In a major boost to efforts to promote
research to combat antimicrobial resistance (AMR), Bengaluru-based Centre for Cellular and
Molecular Platforms (C-CAMP) has signed a Memorandum of Understanding (MoU) with
International Health Management Associates (IHMA), a global organisation that has been
involved in supporting anti-infective and diagnostic development studies for over 25 years.
Under the pact, C-CAMP and IHMA will jointly facilitate microbiology-related studies for
clinical trials, surveillance studies, mentorship programmes and other activities with the
view to promote new drug and vaccine discovery in the area of anti-infectives and foster
new-age diagnostic device development to address the growing problem of antimicrobial
resistance.
C-CAMP is a major bioresearch & innovation hub in the country with a portfolio spread over
the entire life sciences spectrum. The Centre’s programme in the area of antimicrobial
resistance is designed to identify and accelerate the commercialization of innovations in
AMR. Its analytical and technology platforms are accessible to researchers in a service
mode. It is also a member of the CARB-X Global Accelerator Network, a league of 10 top
organizations combating antimicrobial resistance across the USA and Europe.
IHMA, in turn, is a global microbiology research laboratory that provides extensive services
to support the pharmaceutical industry. Their portfolio comprises more than 250
healthcare institutions globally that can be leveraged to carry out clinical trials and
surveillance studies. It has vast experience with the identification and susceptibility testing
of bacterial species. It has a diverse library of clinically relevant phenotypically and
genotypically characterized bacterial and fungal isolates that can be used to assist with
profiling of anti-infective agents during development.
“AMR is widely acknowledged as the biggest threat to 21 st century medicine. As innovators
across the world race to develop next generation antimicrobials and vaccines, it is crucial
that the regulatory and commercial routes to success for these paths are smooth and
obstacle-free. We are delighted to announce that this MoU with IHMA will bring a world-
class 360-degree service model to Indian innovators in the drug discovery arena along with
exposure to global regulatory standards”, said Dr.TaslimarifSaiyed, C-CAMP’s CEO and
Director.
Darcie Carpenter Ph.D., CIC, Director Global Business Development, IHMA welcoming the
MoU said “The IHMA Team is very excited about collaborating with C-CAMP. This MoU
with C-CAMP will help provide additional support to Indian innovators to create the next
generation antibiotics to fight AMR.” (India Science Wire)
